Choroidal Neovascularization – Pipeline Review, 2019

Choroidal neovascularization (CNV) is the formation of new blood vessels in the choroid layer of the eye. Choroidal neovascularization is a common cause of neovascular degenerative maculopathy. Choroidal neovascularization can be caused due to macular degeneration, myopia, ocular trauma, and others. Choroidal neovascularization creates a sudden deterioration of central vision, color disturbances, and metamorphopsia. Choroidal neovascularization is detected by using preferential hyperacuity perimetry. According to the article published in 2014, Pathologic myopia has been affecting up to 3% of the global population. Out of which, a substantial proportion of patients develop myopic CNV.

Current treatment for choroidal neovascularization includes anti-VEGF drugs, thermal laser treatment or photodynamic therapy (PDT). Some of the Food and Drug Administration (FDA) approved angiogenesis inhibitors include pegaptanib, ranibizumab, and bevacizumab. Choroidal neovascularization (CNV) can also be treated with photodynamic therapy coupled with a photosensitive drug such as verteporfin (Visudyne).

Research Institutes and pharmaceutical companies have focussed on studying and developing new methods for the treatment of choroidal neovascularization. For instance; E10030, which is being studied by the Ophthotech Corporation, is currently in phase-3 clinical trials for the study of the Safety and Efficacy study of Fovista (E10030) intravitreous administration in combination with Lucentis compared to Lucentis monotherapy.

Currently, more than 50% of the pipeline candidates for choroidal neovascularization are in phase 1 and phase 2 stage. Majority of the studies have been sponsored by pharmaceutical companies.

Report Description

The report on ‘Choroidal Neovascularization – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for choroidal neovascularization. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for choroidal neovascularization.

The report on ‘Choroidal Neovascularization – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for choroidal neovascularization


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for choroidal neovascularization


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary